MA26859A1 - Forme posologique de medicament commandée par un hydrogel. - Google Patents

Forme posologique de medicament commandée par un hydrogel.

Info

Publication number
MA26859A1
MA26859A1 MA26695A MA26695A MA26859A1 MA 26859 A1 MA26859 A1 MA 26859A1 MA 26695 A MA26695 A MA 26695A MA 26695 A MA26695 A MA 26695A MA 26859 A1 MA26859 A1 MA 26859A1
Authority
MA
Morocco
Prior art keywords
drug
dosage form
water
hydrogel
nucleus
Prior art date
Application number
MA26695A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Lincoln Smith Kelly
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26859A1 publication Critical patent/MA26859A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Sociétés dites : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 23/12/1999 60/171,968 Voir en annexe le titre de l'invention et le texte de l'abrégé "Forme posologique de médicament commandée par un hydrogel" Une forme posologique à libération contrôlée comprend un noyau enrobé, le noyau comprenant une composition contenant un médicament et une composition pouvant gonfler dans l'eau, chacune occupant des régions distinctes dans le noyau. La composition contenant un médicament comprend un médicament à faible solubilité et un agent d'entraînement de médicament. L'enrobage autour du noyau est perméable à l'eau et insoluble dans l'eau et comporte au moins un orifice de libération. Diverses formulations ayant des profils spécifiques de libération de médicament sont décrites.
MA26695A 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel. MA26859A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17196899P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
MA26859A1 true MA26859A1 (fr) 2004-12-20

Family

ID=22625827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26695A MA26859A1 (fr) 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel.

Country Status (42)

Country Link
US (3) US20020015731A1 (fr)
EP (2) EP1967185A1 (fr)
JP (1) JP4100910B2 (fr)
KR (1) KR100523127B1 (fr)
CN (1) CN1402632A (fr)
AP (1) AP2002002553A0 (fr)
AR (1) AR027091A1 (fr)
AT (1) ATE392890T1 (fr)
AU (1) AU783685B2 (fr)
BG (1) BG106865A (fr)
BR (1) BR0016708A (fr)
CA (1) CA2395333C (fr)
CR (1) CR6656A (fr)
CZ (1) CZ20022046A3 (fr)
DE (1) DE60038698T2 (fr)
DK (1) DK1242055T3 (fr)
DZ (1) DZ3228A1 (fr)
EA (1) EA004370B1 (fr)
EE (1) EE200200361A (fr)
ES (1) ES2302705T3 (fr)
GE (1) GEP20043334B (fr)
GT (1) GT200000222A (fr)
HU (1) HUP0301242A3 (fr)
IL (1) IL149224A0 (fr)
IS (1) IS6340A (fr)
MA (1) MA26859A1 (fr)
MX (1) MXPA02006328A (fr)
NO (1) NO20022970L (fr)
NZ (1) NZ518281A (fr)
OA (1) OA12128A (fr)
PA (1) PA8509001A1 (fr)
PE (1) PE20010985A1 (fr)
PL (1) PL357535A1 (fr)
PT (1) PT1242055E (fr)
SI (1) SI1242055T1 (fr)
SK (1) SK8572002A3 (fr)
SV (1) SV2002000250A (fr)
TN (1) TNSN00253A1 (fr)
TR (1) TR200201646T2 (fr)
WO (1) WO2001047500A1 (fr)
YU (1) YU35302A (fr)
ZA (1) ZA200204960B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028253A1 (es) 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000226A2 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004069228A2 (fr) * 2003-02-07 2004-08-19 Omega Farma Ehf. Formules de venlafaxine a liberation prolongee
WO2004098572A1 (fr) * 2003-05-06 2004-11-18 Ranbaxy Laboratories Limited Liberation biphasique de glipizide contenu dans une forme pharmaceutique osmotique monocompartiment
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2006045152A1 (fr) * 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Procede ameliore de preparation de comprimes
WO2006072878A1 (fr) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation
GB0504547D0 (en) * 2005-03-04 2005-04-13 Delsol Products Ltd Personal lubricant
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
WO2007057762A2 (fr) * 2005-11-16 2007-05-24 Pfizer Limited Forme posologique a liberation controlee
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
CN101439026B (zh) * 2007-11-23 2011-04-06 北京红林制药有限公司 含有多沙唑嗪或其盐的控释制剂及其制备方法
CA2715584A1 (fr) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Comprime oral a liberation controlee
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101284368B1 (ko) 2010-07-09 2013-07-15 서울대학교산학협력단 나노섬유시트 기재의 경구용 약물의 제어 전달을 위한 시스템
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
WO2014119836A1 (fr) * 2013-01-30 2014-08-07 Daewoong Co., Ltd. Composition pharmaceutique pour la protection des plaies, l'hémostase, ou la prévention d'adhérence dans le tractus gastro-intestinal
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
EP3821882A1 (fr) 2013-03-14 2021-05-19 Amgen Inc. Composés hétérocycliques et leurs utilisations
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (fr) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
CA3053818A1 (fr) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Composes pharmaceutiques aryle, heteroaryles et heterocycliques pour le traitement de troubles medicaux
EP3841086B1 (fr) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux liés au facteur d du complément
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
IL291452B1 (en) 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
CN114845708A (zh) 2019-12-19 2022-08-02 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
EP4178549A1 (fr) * 2020-07-10 2023-05-17 Adare Pharmaceuticals, Inc. Compositions pharmaceutiques orales pouvant gonfler
US20240325388A1 (en) 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
CA3193488A1 (fr) 2020-09-23 2022-03-31 Jason Allan Wiles Composes pharmaceutiques pour le traitement de troubles a mediation par complement
WO2022251620A1 (fr) * 2021-05-28 2022-12-01 Amgen Inc. Formulations d'aprémilast
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑
EP4479092A4 (fr) * 2022-02-14 2026-03-04 Purdue Research Foundation Sels polymères destinés à améliorer l'administration de médicament à partir de dispersions solides amorphes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IT1165797B (it) * 1982-10-18 1987-04-29 Consiglio Nazionale Ricerche Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5151450A (en) * 1990-02-22 1992-09-29 Tokyo Tanabe Company, Limited Antiulcer substance
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
ATE106015T1 (de) * 1990-09-28 1994-06-15 Pfizer Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält.
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
PT100944B (pt) * 1991-10-10 2000-02-29 Alza Corp Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
KR100355130B1 (ko) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5607696A (en) * 1995-02-10 1997-03-04 Alza Corporation Osmotic membrane and delivery device
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
FR2744733B1 (fr) * 1996-02-08 1998-04-24 Ascometal Sa Acier pour la fabrication de piece forgee et procede de fabrication d'une piece forgee
IT1290764B1 (it) * 1996-05-03 1998-12-10 Vevy Europ S P A Pentapeptide per la preparazione di composizioni dermo- farmaceutiche e cosmetiche per il trattamento di lesioni od affezioni cutanee
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6245200B1 (en) 1999-12-10 2001-06-12 Sandia Corporation Photo-oxidation method using MoS2 nanocluster materials
WO2001047498A2 (fr) * 1999-12-23 2001-07-05 Pfizer Products Inc. Forme de dosage d'un medicament stratifie entraine par un hydrogel
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form

Also Published As

Publication number Publication date
TNSN00253A1 (fr) 2002-05-30
ATE392890T1 (de) 2008-05-15
AP2002002553A0 (en) 2002-06-30
JP4100910B2 (ja) 2008-06-11
CR6656A (es) 2004-04-29
EA004370B1 (ru) 2004-04-29
DE60038698T2 (de) 2009-05-07
US20110182947A1 (en) 2011-07-28
NO20022970D0 (no) 2002-06-20
GEP20043334B (en) 2004-03-10
US9028870B2 (en) 2015-05-12
EP1242055A1 (fr) 2002-09-25
AR027091A1 (es) 2003-03-12
PT1242055E (pt) 2008-07-02
EP1242055B1 (fr) 2008-04-23
NZ518281A (en) 2005-01-28
CZ20022046A3 (cs) 2002-11-13
PL357535A1 (en) 2004-07-26
ZA200204960B (en) 2003-10-02
SI1242055T1 (sl) 2008-08-31
KR100523127B1 (ko) 2005-10-20
BG106865A (bg) 2003-03-31
MXPA02006328A (es) 2002-12-13
AU783685B2 (en) 2005-11-24
ES2302705T3 (es) 2008-08-01
SK8572002A3 (en) 2002-12-03
CA2395333C (fr) 2009-01-13
US20020015731A1 (en) 2002-02-07
EA200200595A1 (ru) 2002-12-26
YU35302A (sh) 2005-03-15
CN1402632A (zh) 2003-03-12
DZ3228A1 (fr) 2001-07-05
IL149224A0 (en) 2002-11-10
WO2001047500A1 (fr) 2001-07-05
EP1967185A1 (fr) 2008-09-10
GT200000222A (es) 2002-06-14
TR200201646T2 (tr) 2002-11-21
BR0016708A (pt) 2002-10-08
HUP0301242A2 (hu) 2004-05-28
EE200200361A (et) 2003-10-15
OA12128A (en) 2006-05-05
PE20010985A1 (es) 2001-09-28
IS6340A (is) 2002-04-12
JP2003518489A (ja) 2003-06-10
CA2395333A1 (fr) 2001-07-05
US20070087057A1 (en) 2007-04-19
DK1242055T3 (da) 2008-07-21
KR20020070330A (ko) 2002-09-05
AU2018901A (en) 2001-07-09
HUP0301242A3 (en) 2006-07-28
NO20022970L (no) 2002-06-20
SV2002000250A (es) 2002-02-05
PA8509001A1 (es) 2002-02-21
DE60038698D1 (de) 2008-06-05

Similar Documents

Publication Publication Date Title
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
EP0966966A3 (fr) Forme posologique de néfadozone
EP1992336A3 (fr) Forme galénique pour la délivrance colique de principes actifs
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
CA2371940A1 (fr) Amidon pregelatinise dans une formulation a liberation regulee
EP0382066A3 (fr) Utilisation de l'acide dihydroliponique comme agent analgésique, antiphlogistique et/ou cytoprotecteur
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DK1187611T3 (da) Oftalmiske histaminholdige sammensætninger og anvendelse deraf
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
CA2382426A1 (fr) Melange pharmaceutique d'ethinylestradiol et de drospirenone utilise en tant que contraceptif
EP1450739A1 (fr) Gel nasal hydratant et applicateur
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GEP20043377B (en) Pharmaceutical Complex
WO2001070184A3 (fr) Composition contenant des monoterpenes destinee a une administration orale topique